Precise Oncology Billing Services for Cancer Care Practices
Oncology billing carries the highest financial stakes in outpatient medicine. A single miscoded chemotherapy drug, a missing prior authorization, or an infusion hierarchy error on a high-cost regimen can mean thousands of dollars in denied revenue. Theiatrics handles every layer of it with the precision that oncology demands.
Oncology Services Theiatrics Bills For
- Chemotherapy drug billing (J-code and Q-code)
- Immunotherapy and biologic infusion billing
- Targeted therapy and hormone therapy billing
- Chemotherapy infusion administration (96413, 96415)
- Non-chemotherapy infusion billing (96365, 96367)
- Subcutaneous and intramuscular injection billing
- Supportive care drug billing (antiemetics, growth factors)
- Biosimilar drug coding and interchangeability billing
- Radiation oncology billing (IMRT, SBRT, brachytherapy)
- Bone marrow biopsy and aspiration billing
- Oncology E&M visit coding (99202–99215)
- Laboratory and pathology claims coordination
⚠️ Buy-and-Bill Drug Margin Protection
For oncology practices operating under buy-and-bill, every dollar of drug margin depends on accurate HCPCS J-code selection, correct dosage unit billing, and timely prior authorization. A single miscoded chemotherapy drug on a high-cost regimen can represent a $5,000 to $50,000 per-claim revenue discrepancy. Theiatrics treats every oncology drug claim with that level of financial attention.
Other Service
Optimize Operations for Maximum Efficiency
Contact us to explore how our consulting can position your business as a frontrunner.
What Makes Oncology Billing Services Exceptionally Complex?
Oncology billing sits in a category of its own among medical specialties. A single infusion visit for a patient receiving a modern immunotherapy regimen might involve a high-cost biologic drug billed by the milligram, a chemotherapy administration code, multiple add-on administration codes following infusion hierarchy rules, supportive care medications each with their own J-codes, and an evaluation and management visit coded at the appropriate level of complexity. Every element on that claim must be correct, and every element carries material financial consequence.
The drug billing component alone requires a detailed understanding of HCPCS J-codes, dosage unit calculations, the difference between how Medicare and commercial payers price oncology drugs, and how biosimilar interchangeability rules affect code selection and reimbursement rates. For practices operating under the buy-and-bill model, drug margin depends entirely on the accuracy of drug billing combined with careful attention to acquisition cost versus Average Sales Price reimbursement.
On top of drug billing, oncology practices deal with prior authorization requirements that vary by drug, by payer, and by clinical indication, often requiring detailed clinical documentation of the patient's cancer type, staging, treatment history, and the clinical rationale for the chosen regimen. Authorization denials for high-cost drugs leave the practice in the difficult position of either appealing while the patient waits or administering the drug at financial risk.
Theiatrics brings the specialty depth that oncology billing requires. We understand the J-code landscape, the infusion hierarchy, the buy-and-bill economics, the prior authorization processes for major payers, and the documentation requirements that separate a paid claim from a denied one in this uniquely high-stakes billing environment.
Oncology Drug Categories We Bill With Precision
Traditional Chemotherapy
Cytotoxic agents administered intravenously or by other routes require J-codes billed per dosage unit. Correct unit calculation based on actual milligrams administered is critical to accurate reimbursement and audit compliance.
Immunotherapy & Checkpoint Inhibitors
Modern immunotherapy agents including PD-1 and PD-L1 inhibitors are among the highest-cost drugs in oncology. Correct J-code assignment and mg-based dosage billing are essential to capturing the full reimbursement these drugs warrant.
Targeted Therapy & Biologics
Monoclonal antibodies and targeted agents have distinct J-codes based on drug name and formulation. Biosimilar versions of reference biologics may have separate codes with interchangeability designations that affect reimbursement under some payer contracts.
Hormone Therapy
Androgen deprivation therapy, aromatase inhibitors, and other hormone-based treatments used in prostate, breast, and other hormone-sensitive cancers require precise coding of both the drug and the injection or implant administration service.
Supportive Care Medications
Antiemetics, colony-stimulating factors, bone-modifying agents, and other supportive care drugs administered in the infusion suite each require their own J-code and dosage unit calculation alongside the primary chemotherapy billing.
Biosimilars & New Agents
Biosimilar drugs approved as interchangeable with reference biologics may have distinct billing requirements. New oncology agents approved mid-year may receive temporary Q-codes or miscellaneous J-codes until CMS assigns permanent codes in the next HCPCS update cycle.
Infusion Hierarchy: The Rule That Determines Your Oncology Reimbursement
Chemotherapy as Initial Infusion (Highest Hierarchy)
When a chemotherapy drug is administered by infusion, it is always billed as the primary service regardless of which drug was administered first. The initial chemotherapy infusion code is non-time-based for the first infusion in a day, and the drug is billed separately using its J-code.
Sequential Chemotherapy Infusion
Each additional chemotherapy drug administered sequentially after the initial infusion is billed as a sequential add-on. Sequential means one infusion finishes before the next begins. This code is used once per additional chemotherapy drug regardless of infusion duration.
Concurrent Infusion
When a second infusion runs simultaneously with the primary infusion through a different IV line, it is billed as concurrent. Concurrent infusions are not reported separately for each 15-minute increment. Only one concurrent infusion add-on is reported per concurrent drug administered.
Non-Chemotherapy Infusion (Lower Hierarchy)
When a non-chemotherapy drug such as supportive care medication is infused in the same session as a chemotherapy drug, the non-chemo infusion is billed as secondary to the chemotherapy service, using the sequential non-chemotherapy add-on code rather than the initial infusion code.
Injection Services (Lowest Hierarchy)
Subcutaneous and intramuscular injections administered in the same encounter as infusions are billed as injection add-ons. Each injection is reported separately using the appropriate administration code and the drug’s J-code, and each is subordinate to the infusion services in hierarchy.
Our Complete Oncology Billing Services
Prior Authorization Management
We manage prior authorization requests for all oncology drugs across every commercial payer and Medicare Advantage plan in your payer mix. We compile the required clinical documentation, track approval status, and manage appeals when initial authorization is denied.
Chemotherapy Drug Coding
Our oncology billing specialists assign the correct J-code for every drug administered, calculate dosage units based on actual milligrams given, and apply new codes for recently approved agents, including temporary Q-codes and miscellaneous J-codes where applicable.
Infusion Hierarchy Compliance
We apply infusion hierarchy rules accurately across all payers, ensuring the correct initial, sequential, and concurrent administration codes are selected for every infusion session and that each add-on service is sequenced correctly to maximize reimbursement without triggering bundling denials.
Eligibility & Coverage Verification
We verify insurance eligibility and oncology-specific drug coverage before each treatment session, confirming prior authorization status, cost-sharing responsibilities, and any coverage limitations that could affect claim submission or patient financial counseling.
Documentation Review & Support
We review treatment documentation for coding accuracy and compliance before billing, flagging any gaps between the clinical record and the proposed claim that could create denial risk, audit exposure, or underpayment under medical necessity review.
Denial Management & Appeals
When a claim is denied, we analyze the reason, correct the issue, and resubmit within 48 hours. For clinical necessity denials involving high-cost oncology drugs, we prepare detailed peer-to-peer appeal support packages with published clinical guidelines and supporting literature references.
Radiation Oncology Billing
We manage billing for external beam radiation therapy, IMRT, SBRT and stereotactic radiosurgery, brachytherapy, and simulation services. Radiation oncology uses distinct CPT codes in the 77000–77999 range with separate technical and professional component billing considerations.
AR Follow-Up & Collections
We work all unpaid and underpaid oncology claims systematically, with particular attention to high-dollar drug claims where underpayments have the most material impact. No aging account is left without active follow-up until it is resolved or correctly written off.
Revenue Cycle Reporting
You receive regular reports on drug-level claim performance, infusion code reimbursement trends, authorization approval rates, denial root causes, and days in AR by payer so your practice has the financial visibility it needs to manage the high-cost nature of oncology services.
Oncology Billing Challenges We Solve Every Day
Incorrect Drug Dosage Unit Billing
Each oncology J-code has a defined unit of measure, typically a specific number of milligrams per billing unit. When the actual dose administered is not divided correctly by the billing unit, the practice either underbills or risks overpayment recoupment. For a drug priced at $50 per billing unit, a unit calculation error on a 500mg dose can mean hundreds of dollars per claim in lost or at-risk revenue.
How we help: We calculate dosage units from the actual milligrams documented in the administration record for every drug on every claim, not from the order or the standard dose protocol.
Authorization Denials for High-Cost Drugs
Prior authorization denials for immunotherapy and targeted therapy drugs are among the most costly claim denials in all of medicine. When a practice administers a high-cost drug without authorization, or when an authorization expires mid-treatment, the financial exposure can reach tens of thousands of dollars per patient per cycle.
How we help: We manage the entire authorization lifecycle from initial request through approval, including tracking expiration dates, submitting concurrent authorization extensions, and managing appeals for initial denials with clinical documentation packages.
Infusion Hierarchy Errors
When two or more drugs are infused in the same session, the wrong administration code sequence results in bundling denials or systematic underpayment. Billing a non-chemotherapy infusion as the primary service when a chemotherapy drug was also administered is one of the most common hierarchy errors in oncology billing.
How we help: We apply infusion hierarchy rules across all payers for every multi-drug infusion session, ensuring chemotherapy takes primary position and all add-on services are sequenced correctly based on CMS and payer-specific hierarchy guidance.
New Drug and Biosimilar Coding Gaps
New oncology drugs approved by the FDA are not always assigned a permanent J-code immediately. They may be billed under a temporary Q-code or a miscellaneous code. Practices that are unaware of new code assignments continue billing miscellaneous codes after a specific code is available, which results in claim delays and payer audit flags.
How we help: We monitor HCPCS quarterly updates and FDA drug approval announcements proactively, updating our code reference library when new oncology codes are assigned and ensuring your claims transition to specific codes as soon as they become available.
Medical Necessity Documentation Gaps
Payers increasingly conduct post-payment medical necessity reviews for high-cost oncology drugs, particularly immunotherapy agents used off-label or in clinical trial settings. When the clinical record does not clearly support the FDA-approved or compendium-listed indication, the claim is vulnerable to post-payment denial and recoupment.
How we help: We review treatment documentation for medical necessity compliance before billing and flag cases where the clinical record may not adequately support the indication for review by your clinical team before the claim is submitted.
Drug Margin Erosion from Underpayment
Commercial payers frequently apply drug pricing methodologies that differ from Medicare’s ASP-based rates. Some payers apply contracted pricing schedules that should be reviewed against actual drug acquisition costs to ensure margin is being protected. Practices that do not review drug-level remittances lose margin without knowing it.
How we help: We review oncology drug reimbursement at the line-item level, comparing payer payments against expected rates under Medicare and contracted commercial terms, and pursuing underpayments through the correct appeal process before they become unrecoverable.
Oncology Billing Across All Cancer Types and Treatment Modalities
Hematologic Malignancies
Leukemia, lymphoma, myeloma, and myelodysplastic syndrome billing including bone marrow biopsy, CAR-T therapy coordination, and high-cost biologic agents.
Solid Tumor Oncology
Lung, colorectal, breast, gastric, and hepatocellular carcinoma billing including complex multi-drug regimen administration and targeted therapy coding.
Neuro-Oncology
Brain tumor treatment billing including temozolomide, bevacizumab, and radiation oncology coordination for glioblastoma and other central nervous system malignancies.
Genitourinary Oncology
Prostate, bladder, renal, and testicular cancer billing including androgen deprivation therapy, checkpoint inhibitors, and hormone therapy injection administration.
Gynecologic Oncology
Ovarian, cervical, endometrial, and vulvar cancer billing including PARP inhibitor coding, bevacizumab combination regimens, and chemosensitization billing.
Melanoma & Skin Cancers
Melanoma immunotherapy billing including ipilimumab, nivolumab, and pembrolizumab J-codes, BRAF-targeted therapy, and Merkel cell carcinoma treatment billing.
Radiation Oncology
IMRT, SBRT, stereotactic radiosurgery, brachytherapy, and simulation billing using CPT 77000-77799 range codes with technical and professional component separation.
Palliative & Supportive Care
Symptom management, palliative chemotherapy, pain management infusions, and supportive care drug billing alongside active treatment regimens.
Why Oncology Practices Choose Theiatrics for Billing
The True Financial Stakes of Oncology Billing Errors
In most medical specialties, a coding error might cost a practice $50 to $500 per claim. In oncology, the same category of error — a miscoded drug, a wrong dosage unit, a missing authorization — can cost $5,000 to $50,000 or more on a single claim involving a modern immunotherapy or targeted therapy agent. The financial stakes of billing accuracy in oncology are simply in a different category from most other specialties.
For a practice administering $3 million per year in oncology drugs under buy-and-bill, even a 2% systematic undercoding rate represents $60,000 in annual revenue that is not being captured. Add authorization-related denials, infusion hierarchy errors, and underpayments from commercial payers applying non-ASP pricing methodologies, and the total revenue gap can reach 8% to 12% of potential annual collections.
When Theiatrics takes over an oncology practice’s billing, we begin with a 12-month claims audit that quantifies these gaps before we manage a single new claim. This audit typically surfaces both immediate recovery opportunities and the process improvements that protect revenue going forward.
Ready to Protect and Maximize Your Oncology Practice Revenue?
Let Theiatrics handle the drug coding precision, authorization management, infusion hierarchy compliance, and denial resolution that oncology billing demands. Start with a free billing review and see exactly where your revenue stands.
Schedule My Free Audit →Answers to What Oncology Billing Providers Ask Us Most
Answers to the questions oncology practice administrators and billing directors ask us most when evaluating specialized billing support for their cancer care practice.
Find Lost Revenue Before Claims Are Filed
We review recent encounters, identify missed or undercoded charges, and show exact revenue impact — before you commit to anything.
90 days of encounters reviewed
Codes matched with documentation
Exact dollar value identified
From certified specialists
100% risk-free audit
More Info
Get in touch with us
5900 Balcones Drive Ste 7988, Austin, Texas, 78731, USA
Follow Us On
© 2026 Theiatrics. All Rights Reserved